Age at introduction to complementary solid food and food allergy and sensitization: A systematic review and meta-analysis. Miércoles 28 de octubre

De

 Age at introduction to complementary solid food and food allergy and sensitization: A systematic review and meta-analysis


Authors: John A Burgess  1 , Shyamali C Dharmage  1   2 , Katrina Allen  2   3 , Jennifer Koplin  2 , Vanessa Garcia-Larsen  4 , Robert Boyle  5 , Nilakshi Waidyatillake  1 , Caroline J Lodge  1


Abstract


Background and objective: An infant's age at introduction of complementary solids may contribute to food allergy. We aimed to synthesize the literature on the association between age at introduction of complementary solids, excluding milk products, and food allergy and sensitization.


Design: We searched the electronic databases PubMed and EMBASE (January 1946-February 2017) using solid food, allergy and sensitization terms.


Methods: Two authors selected papers according to inclusion criteria, identifying 16 cohort studies, 1 case-control study and 8 randomized controlled trials (RCTs). Pooled effects across studies were estimated using random-effects meta-analysis.


Results: Cohort studies-Introducing complementary solids at age ≥ 4 months vs <4 months was not associated with food allergy (OR 1.22; 95% CI, 0.76-1.96) but was associated with food sensitization (OR 1.93; 95% CI 1.57-2.38). First exposure from age 4 to 6 months vs <4 months was not associated with food allergy (OR 1.01; 95% CI, 0.64-1.60) but was associated with food sensitization (OR 2.46; 95% CI 1.55-3.86). Randomized controlled trials-Egg exposure from age 4 months was associated with reduced egg allergy (OR 0.63, 95% CI, 0.44-0.90) and sensitization (OR 0.76, 95% CI, 0.51-0.95). Peanut exposure from age 4 months compared to delayed exposure was associated with reduced peanut allergy (OR 0.28, 95% CI 0.14-0.57).


Conclusions: We found no evidence from observational studies that introducing solids before 4 months protected against food allergy, but there was evidence for protection against food sensitization. From RCTs, introducing egg from 4 to 6 months and peanut from 4 to 11 months reduced the risk of egg allergy, peanut allergy and egg sensitization. PROSPERO systematic review registry (CRD42016033473).


10.1111/cea.13383

Comentarios

Publicar un comentario

Entradas populares de este blog

La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo

De
La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo Autores: A. López Mateos, M.J. Sánchez Pujol y J.F. Silvestre Salvador Resumen: La urticaria crónica es una entidad relativamente frecuente en la práctica clínica habitual, cuyo diagnóstico se establece de forma clínica. Sin embargo, existen ocasiones en las que está indicada la realización de una biopsia cutánea para confirmar el diagnóstico y diferenciarla de otras patologías que pueden cursar con erupciones urticariformes. En este trabajo revisamos los hallazgos histopatológicos que podemos encontrar tanto en la urticaria crónica como en las patologías que plantean un diagnóstico diferencial. Con base en ello, proponemos un algoritmo que recoge las indicaciones para realizar una biopsia cutánea y la orientación del diagnóstico en función de los hallazgos histopatológicos que encontremos en la misma. DOI:   https://doi.org/10.1016/j.ad.2020.11.016
Leer más

Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Fecha: Miércoles 12 de junio

De
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Authors: Castells M1, Butterfield J2. 1 Division of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital Mastocytosis Center, Boston, Mass. Electronic address: mcastells@bwh.harvard.edu. 2 Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minn. Abstract: Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in addition can have organ damage from the local effects of tissue infiltration by clonal mast cells. Patients with nonclonal MCAS may have chronic or episodic mast cell activation symptoms with an increase in serum tryptase and/or urinary metabolites of histamine, prostaglandin D2, and leukotrienes. Symptoms of MCAS and SM can be managed by blockade of mediator receptors (H1 and H2 antihistamines, leukotriene r...
Leer más

Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Miércoles 21 de agosto

De
Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Authors:  Hendricks AJ1, Mills BW2, Shi VY3. 1 University of Arizona College of Medicine, Tucson, AZ USA. 2 Texas Tech Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX USA. 3 University of Arizona Department of Medicine, Division of Dermatology, Tucson, AZ USA. Electronic address: vshi@email.arizona.edu. Abstract: Dysbiosis is a key pathogenic factor in the cycle of  skin  barrier impairment and inflammation in  atopic   dermatitis  (AD).  Skin  microbial composition in AD is characterized by increased presence of Staphylococcus aureus (S. aureus) and decrease in microbial diversity and commensal  bacterial  species. Attenuation of S. aureus-driven inflammation aids in breaking the itch-scratch cycle via modulation of the cutaneous immune response.  Skin   bacterial   transplant  (SBT), a f...
Leer más